Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Alnylam Pharmaceuticals, Inc.”

376 pharma patents match "Alnylam Pharmaceuticals, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 376
Index total 30,257
Page 5 / 16

Quick answer

This filtered view shows 376 pharmaceutical patents matching "Alnylam Pharmaceuticals, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

376 results for “Alnylam Pharmaceuticals, Inc.” · 30,257 patents in full index Clear search

  1. US 11034958

    Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted

  2. US 11034957

    Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jun 15, 2021 · Expires Jun 10, 2041

    granted

  3. US 11028392

    Compositions and methods for inhibiting expression of the ALAS1 gene

    Alnylam Pharmaceuticals, Inc. · Granted Jun 8, 2021 · Expires Jun 3, 2041

    granted

  4. US 10995336

    Serpina1 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted May 4, 2021 · Expires Apr 29, 2041

    granted

  5. US 10988768

    TMPRSS6 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 27, 2021 · Expires Apr 22, 2041

    granted

  6. US 10982215

    Polynucleotide agents targeting programmed cell death 1 ligand 1 (PD-L1) and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted

  7. US 10982212

    Conserved HBV and HCV sequences useful for gene silencing

    Alnylam Pharmaceuticals, Inc. · Granted Apr 20, 2021 · Expires Apr 15, 2041

    granted

  8. US 10968452

    Polynucleotide agents targeting aminolevulinic acid synthase-1 (ALAS1) and uses thereof

    Alnylam Pharmaceuticals, Inc. · Granted Apr 6, 2021 · Expires Apr 1, 2041

    granted

  9. US 10954516

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Alnylam Pharmaceuticals, Inc. · Granted Mar 23, 2021 · Expires Mar 18, 2041

    granted

  10. US 10946107

    Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, HAO1) and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Mar 16, 2021 · Expires Mar 11, 2041

    granted

  11. US 10934545

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted

  12. US 10933081

    Myostatin iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted

  13. US 10934544

    Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Mar 2, 2021 · Expires Feb 25, 2041

    granted

  14. US 10920223

    Serpina1 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Feb 16, 2021 · Expires Feb 11, 2041

    granted

  15. US 10913950

    TMPRSS6 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Feb 9, 2021 · Expires Feb 4, 2041

    granted

  16. US 10889813

    Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jan 12, 2021 · Expires Jan 7, 2041

    granted

  17. US 10883107

    Polynucleotide agents targeting factor XII (hageman factor) (F12) and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Jan 5, 2021 · Expires Dec 31, 2040

    granted

  18. US 10851377

    Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder

    Alnylam Pharmaceuticals, Inc. · Granted Dec 1, 2020 · Expires Nov 26, 2040

    granted

  19. US 10844384

    Glucokinase (GCK) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Nov 24, 2020 · Expires Nov 19, 2040

    granted

  20. US 10829763

    TMPRSS6 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Nov 10, 2020 · Expires Nov 5, 2040

    granted

  21. US 10814007

    Angiotensinogen (AGT) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Oct 27, 2020 · Expires Oct 22, 2040

    granted

  22. US 10808246

    Oligonucleotide-ligand conjugates and process for their preparation

    Alnylam Pharmaceuticals, Inc. · Granted Oct 20, 2020 · Expires Oct 15, 2040

    granted

  23. US 10806791

    Carbohydrate conjugates as delivery agents for oligonucleotides

    Alnylam Pharmaceuticals, Inc. · Granted Oct 20, 2020 · Expires Oct 15, 2040

    granted

  24. US 10767177

    Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Sep 8, 2020 · Expires Sep 3, 2040

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.